74 withdrawn. 74 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 74 | Withdrawn 74 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Healthy: new trials by email Literature Review of Healthy trials Research Report on Healthy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing the Safety of an IGY Supplement on the Gut Microbiome IgY supplement, Placebo - Healthy, Microbiome | Phase 1 / Phase 2 | Withdrawn | Nimble Science Ltd. | 2026-01-01 | 2026-09-30 | |
| Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline - Healthy | Phase 1 | Withdrawn | HealthPartners Institute | 2025-08-30 | 2025-11-25 | |
| A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Withdrawn | Pfizer | 2025-04-28 | 2025-04-24 | |
| A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO - Healthy | Phase 1 | Withdrawn | AstraZeneca | 2024-10-17 | 2025-08-15 | |
| A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body Regimen 1 (Oral primaquine), Regimen 2 (IV primaquine phosphate), Regimen 3 (IV carboxyprimaquine) - Healthy, Pharmacokinetic | Phase 1 | Withdrawn | University of Oxford | 2024-03-01 | 2024-05-06 | |
| Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants Recifercept - Healthy | Phase 1 | Withdrawn | Pfizer | 2023-10-25 | 2023-04-18 | |
| Bioavailability Study of Psilocybin in Normal Adults Oral Psilocybin, IV Psilocybin - Healthy | Phase 1 | Withdrawn | University of Wisconsin, Madison | 2023-06-01 | 2023-05-15 | |
| A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants JNJ-77474462 - Healthy | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2023-05-01 | 2025-02-03 | |
| Effect of Basis™ and High Intensity Interval Training (HIIT) on Muscle Metabolism and Exercise Performance NRPT, Placebo oral capsule - Healthy | Phase 1 | Withdrawn | Elysium Health | 2023-02-01 | 2023-02-15 | |
| A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine BI 474121, Placebo, Ketamine hydrochloride - Healthy | Phase 1 | Withdrawn | Boehringer Ingelheim | 2022-11-07 | 2022-08-01 | |
| A Study of LY3526318 in Healthy Male Japanese Participants LY3526318, Placebo, Iohexol - Healthy | Phase 1 | Withdrawn | Eli Lilly and Company | 2022-11-01 | 2026-09-08 | |
| The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects DWP213388, Placebo - Healthy | Phase 1 | Withdrawn | Daewoong Pharmaceutical Co. LTD. | 2022-10-01 | 2024-11-05 | |
| The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear Glycerol - Tympanosclerosis, Thickened Ears | Phase 1 | Withdrawn | Nova Scotia Health Authority | 2022-10-01 | 2024-08-21 | |
| Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy Subjects HHT120, Placebo - Healthy | Phase 1 | Withdrawn | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | 2022-07-01 | 2023-02-01 | |
| A Study of Butamirate Citrate Syrup Versus (vs) Sinecod Syrup (Vanilla) in Adult Healthy Study Volunteers Butamirate citrate, Sinecod - Healthy | Phase 1 | Withdrawn | McNeil AB | 2022-03-18 | 2022-05-20 | |
| A Study of JNJ-70075200 in Healthy Participants JNJ-70075200, Placebo - Healthy | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2022-03-01 | 2022-01-05 | |
| A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants JNJ-75105186, Placebo - Healthy | Phase 1 | Withdrawn | Janssen Pharmaceutical K.K. | 2021-11-15 | 2025-02-03 | |
| Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440 Drospirenone/Ethinylestradiol, Midazolam, JNJ-64530440 - Healthy | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2021-06-01 | 2021-03-26 | |
| A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants JNJ-64304500 - Healthy | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2021-05-30 | 2021-09-01 | |
| A Study of JNJ-56136379 in Healthy Participants JNJ-56136379, Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) - Healthy | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2021-05-06 | 2021-07-15 |
Showing 20 of 74. Sign in to see all of them.
Asthma (1) · Communicable Diseases (1) · Depressive Disorder, Major (1) · Dust Mite Allergy (1) · Growth Disorders (1) · HIV Infections (1) · Hemophilia A (1) · Hemophilia B (1) · Hemorrhagic Fever, Ebola (1) · Hypersensitivity (1) · Influenza, Human (1) · Insulin Resistance (1) · Malaria (1) · Pulmonary Disease, Chronic Obstructive (1) · Substance-Related Disorders (1)
Infections (5) · Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (3) · RNA Virus Infections (3) · Respiratory Tract Diseases (3) · Virus Diseases (3) · Disease Attributes (2) · Immune System Diseases (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Mental Disorders (2) · Otorhinolaryngologic Diseases (2) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Blood-Borne Infections (1)
Alprazolam (2) · Ketamine (2) · Midazolam (2) · 8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline (1) · AZD6765 (1) · Allergens (1) · Anti-Allergic Agents (1) · Bevacizumab (1) · Bisoprolol (1) · Ciprofloxacin (1) · Contraceptives, Oral (1) · Curcumin (1) · Digoxin (1) · Dust (1) · Ethinyl Estradiol (1)
Pfizer (8) · Boehringer Ingelheim (7) · Janssen Research & Development, LLC (7) · AstraZeneca (6) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (5) · Janssen Pharmaceutical K.K. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Daewoong Pharmaceutical Co. LTD. (2) · Eli Lilly and Company (2) · NVP Healthcare (2) · Novo Nordisk A/S (2) · University of North Carolina, Chapel Hill (2) · Actavis Inc. (1) · Bausch Health Americas, Inc. (1) · Bristol-Myers Squibb (1)
United States (13) · China (5) · Japan (4) · United Kingdom (3) · South Korea (2) · Belgium (1) · Canada (1) · Germany (1) · Israel (1) · Jordan (1) · Netherlands (1) · Russia (1) · Singapore (1) · South Africa (1) · Thailand (1)
Bae K Seop, M.D. (1) · Borimas Hanboonkunupakarn, Asst. Prof (1) · Bradford Harris, MD (1) · Brendan Smyth, MD (1) · Carin Jorup, MD (1) · Christopher Nicholas, PhD (1) · David Melnick, MD (1) · David P Morris, MD (1)
2014 (2), 2016 (1), 2018 (1), 2023 (1), R01ES012706 (1)